Drug intelligence / Profile preview

shuang bailian mixture

Development stage: Preclinical
Administration: Oral

Overview

Shuang Bailian mixture is a traditional Chinese medicine (TCM) multi-herb combination used particularly as an adjunct in cancer therapy, notably esophageal cancer. Research indicates that SBLM enhances the anti-cancer effect of cisplatin by inhibiting the PI3K-Akt-Bcl-2 signaling pathway, thereby promoting cancer cell apoptosis and overcoming drug resistance. SBLM has demonstrated activity in cell assays and a nude mouse tumor model, notably reducing proliferation, invasion, and tumor size when combined with cisplatin. Its precise herbal composition is not specified in the available literature; however, mechanistic studies support its role as an apoptosis inducer and a regulator of cell signaling pathways in oncology, with primary development and use in China[1].

Brand names: shuang bailian mixture
Other names: SBLM

Beyond the preview

Go deeper on shuang bailian mixture.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on shuang bailian mixture.

Explore the full profile